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I. Introduction 
The AIDS epidemic has ravaged Africa’s cultural landscape in various ways since it first 
emerged as one of the deadliest viruses this generation has seen.  Aside from breaking 
down the traditional family structure and creating enormous healthcare costs for 
individuals, it has also had a salient effect on businesses in Africa.  In the past, companies 
claimed that they could not be held responsible for providing aid with regards to this crisis, 
citing it as a problem to be dealt with by the government or by those individuals infected 
with the virus.  Recently, however, many companies have begun to analyze the benefits of 
providing healthcare to employees, as they begin to face some of the crippling costs 
associated with the disease.  While it may be difficult to convince all companies to provide 
care based on moral standards, economic considerations are far more difficult to dismiss.  
Therefore, it seems beneficial to approach the problem with a profit maximization focus.  
This paper aims to study the feasibility of using a computer system that utilizes statistical 
models, neural networks and fuzzy logic to assist companies with their AIDS programs.  
Furthermore, it will analyze how to market this product.  First, some important background 
information about the AIDS crisis will be provided, focusing on its effects on African 
businesses.  This will be followed by a description of the overall research project, followed 
by a more detailed account of the actual research.  Finally, the prime conclusions will be 
presented in addition to suggestions for future improvements and research. 
 
Background Information 
The AIDS crisis can affect a business in various ways.  From a profit enhancing focus, the 
costs suffered by the company as a result of an HIV infected workforce should determine 
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the level of aid the company ultimately provides.  A company should be willing to pay for 
an AIDS program such that the costs of the program are less than or equal to the benefits 
achieved through use of the  program.  Although it can be difficult to quantify all of the 
effects, it is helpful to discuss them.  For the purposes of this paper, the effects have been 
divided into those that are visible and those that are non-visible.  Another issue companies 
must consider once they have decided to implement an AIDS program is exactly what the 
program should entail.  While some companies choose prevention, others rely on treatment 
as the most effective way to decrease the escalating costs of this epidemic.   
  
II.i. Visible Effects 
First, AIDS affects the actual workforce.  Not only are astonishing rates of people 
dying from AIDS related diseases, but numerous workers are also forced to take 
many sick days.  Once HIV positive employees progress to AIDS, they take 
roughly 30-35 more sick days per year than a healthy employee.  Furthermore, 
during the last year of their lives, employees with AIDS are often put on lighter 
duty.I  Productivity is lost not only from the missing worker but also from healthy 
employees who have to make up for the sick employee’s absence.  The costs of 
absenteeism at work are estimated in the first graph in Exhibit One.  As depicted, 
absenteeism has cost businesses millions of Rand, and is projected to continue its 
steep climb until around 2010, at which point it will continue to grow at a 
decreased rate.  With roughly 20% of the population in South Africa infected with 
HIV,II it seems logical that a large percentage of the workforce will continue to 
spend significant portions of time absent from work.  Absenteeism has a negative 
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effect on production in two major ways.  First, a smaller labor force means less 
employees contributing to production in the short-term.  It also means, however, 
that the cost of training employees will be higher.  According to Aventin and Huard 
“transmission of skills and learning of tacit knowledge would be greatly facilitated 
if skilled HIV-infected employees could remain in their posts longer and in better 
conditions.”III  Due to the sudden loss of workers who are sick from AIDS, healthy 
employees must not only pick up the extra work, but must also take extra time out 
of their schedules to train replacement workers.  The second graph in Exhibit One 
estimates the costs of training and recruitment.  Compared to the first graph, the 
steep incline occurs 4-5 years later.  The true burden of training and recruitment 
lags behind absenteeism costs; therefore, it is a long-term effect with which 
businesses will have to cope.  A reduction in productivity can be expected to follow 
these shifts as companies go through periods with sick and unproductive 
employees, followed by periods with new employees who have yet to achieve full 
productivity.IV  In addition to increased absenteeism, high training and recruitment 
costs and decreased productivity, another visible cost is the pension paid for family 
members and employees as well as death benefits.  These tend to be roughly 3.5 
times a worker’s salary.V  Thus, they are another hefty cost companies can expect 
to pay upon an employee’s death.   
 
II.ii. Non-visible Effects 
While the visible effects are apparent to management, there are other effects on the 
workplace that are far more difficult to track and monitor.VI  These changes involve 
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a shift in the company’s organization and operational structure.VII  As employee 
absenteeism rises and healthy employees are forced to take on extra responsibility, 
employee morale decreases and the definitions typically used to describe each 
position’s responsibilities become skewed.  The constant fluctuation of employees 
leads to confusion regarding the company’s organization.  Furthermore, the shifting 
of extra responsibility to healthy employees can cause these employees to resent 
the organization for failing to properly address the issue, thereby allowing it to 
have a negative effect on those healthy employees who remain with the company.  
This can lead to disloyalty and alienate these employees.VIII  While these effects are 
nearby impossible to quantify, unlike a decrease in labor force and reduction in 
productivity, they nonetheless have a very strong effect on the workplace over time.  
Due to the fact that these are intangible costs, they cannot be included in the 
financial model.  They should, however, be included in discussions of the costs of 
the AIDS crisis and should be considered by companies who are committed to 
eliminating the costs associated with the virus. 
  
II.iii. Treatment  
Many companies have been quick to adopt various methods of treatment, such as 
providing employees with easy access to affordable or free anti-retroviral drugs, 
which are typically too expensive for Africans living with the virus.  Anglo 
American, a large mining conglomerate in South Africa, was one of the first 
companies to establish a healthcare program, offering to subsidize 90% of the cost 
of anti-retroviral drugs for each employee affected as well as one legal spouse.IX  
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Coca-Cola is another good example of a company with operations in Africa that is 
taking a proactive approach towards the problem.  They provide free, confidential 
testing for employees as well as inexpensive drugs.  Furthermore, they have started 
the Coca-Cola AIDS foundation, which will work in conjunction with UNAIDS 
towards treating various people living with the virus.X  Treatment has proven to be 
an extremely cost-effective way of curbing some of the short-term, negative side 
effects of the epidemic.  It significantly decreases absenteeism at work and 
prolongs the average employee life span.  Thus, training costs are seriously reduced 
as employees are able to remain at their jobs for longer periods of time and assist in 
training new hires.  Furthermore, it promotes high employee morale and creates a 
strong bond between the infected worker and the company.  In fact, some insist it 
encourages workers to perform even better on the job, as being discharged would 
mean losing the health benefits associated with the position.  Yet, the high costs of 
antiretroviral drugs have made some companies refuse to provide them for 
employees.  Furthermore, the timing of offering drugs to employees is a critical 
issue.  Companies want to be sure to provide drugs only when the virus has begun 




Despite the vast benefits of treatment, it is important to recognize it as an 
appropriate short-term solution to a long-term problem. While it is incredibly 
useful to treat employees who are currently infected with the virus, companies have 
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also started offering education programs to help prevent further infection among its 
healthy employees.  Clearly, companies can severely reduce future costs by 
retaining a solid base of healthy employees.  Therefore, it is helpful for companies 
to develop a two-pronged approach towards this epidemic: treatment and long with 
containment through education.  Brain Warmuth, head of the South African 
Chamber of Business HIV/AIDS program has noted, “companies are realizing that 
to invest money into managing the HIV/AIDS pandemic will be cheaper than 
addressing the aftermath of AIDS.”XI  Since companies have already seen some of 
the devastating effects the virus has had on their current labor force, they should be 
willing to spend money on programs that would educate the remainder of their 
workforce and secure a large amount of skilled and trained workers for the future. 
 
II. Research Project 
This particular research project is unique in that it is actually a smaller portion of a larger 
research project.  Thus, in order to provide a lucid explanation of the research, it is 
necessary to first explain the project in its entirety.  The project’s final aim is to market a 
computer system to businesses in Africa that would assist them in maintaining better 
managed AIDS programs.  Companies in remote areas could take advantage of the 
advanced medical care available in metropolitan areas at a fraction of the cost by using the 
computer program.  Nurses and other onsite medical staff would be responsible for placing 
an employee’s medical information into the computer program.  This information would 
then be sent to doctors located in the nearby urban region who could recommend 
appropriate treatment or medication.  Therefore, companies benefit from the knowledge of 
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a highly trained, experienced doctor without suffering the staggering costs of having one 
onsite at all times.  This program is not devoid of all costs, however.  The software itself 
must be purchased.  Additionally, companies must prepare appropriately by hiring the 
proper medical staff to achieve the maximum potential of the software.  In order to market 
this product, further information regarding this market and its needs is essential.  To help 
determine the feasibility of this product, a financial model has been created that is driven 
by various inputs and assumptions and calculates the cost or benefit of using the computer 
program.  The inputs include the visible costs of AIDS, the benefits of using the computer 
program and the costs of implementing the program.  While one number can easily define 
certain inputs, such as a worker’s salary, other inputs are more ambiguous, such as 
productivity loss.  These inputs are entered into the program as a range, with a low 
number, high number and base figure.  The model then uses Monte Carlo simulation to run 
through all of the possible scenarios. 
 
IV. Individual Research 
My individual research has dealt with the refinement of the assumptions upon which the 
model relies.  The ultimate goal of the project is to prove that it is in a company’s best 
interest, financially, to purchase our computer software and implement an AIDS program 
that utilizes both prevention and treatment.  In order to do this, the project intends to use a 
financial model to prove that the benefits of using the software outweigh the costs.  The 
model is a pivotal part of the research project.  It is very important that the assumptions in 
the model are based on accurate and reliable information.  Hence, the main goal of my 
individual research was to eliminate as much uncertainty as possible from the assumptions 
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by gaining more factual information and decreasing the range of possible outcomes 
assigned to the inputs.  The more accurate the assumptions, the more accurate the model 
will be.  The model was built prior to the beginning of my individual research.  The inputs 
were given as very broad ranges based on some preliminary research.   However, it was 
important that these ranges were decreased.  Before beginning my research, I ran the model 
based on the broad assumptions.  This produced a “tornado chart,” which is a chart that 
displays the model’s sensitivity to each assumption.  The chart lists each assumption in 
order, beginning with the assumption that has the greatest effect on the model and ending 
with the assumption that has the least effect on the model (see Exhibit Two).  This was 
incredibly useful as it allowed me to pinpoint the assumptions that were most important to 
improving the model.  I researched the top five to six assumptions, put my research into 
the model, ran the model again to create a new tornado chart and repeated the process.  As 
more research was placed in the model, the model’s sensitivity to the assumptions 
decreased.  See Exhibit Three for a copy of the most recent sensitivity chart.   Something 
important to note is that certain inputs still have a very large effect on the model, such as 
the growth rate of pharmaceutical costs.  This can be the result of several factors.  First, 
despite constant research, I could not find reliable information for each input in the model 
and was unable to decrease the margin between the high number and the low number for 
certain assumptions.  Secondly, some numbers do not fit neatly into the model and may 
require further modification.  For a more detailed explanation, please see Section VI: Areas 
for Potential Improvements.     
 A particularly interesting part of my research stemmed from the fact that some of 
the information necessary to fine-tune the model was very difficult to find.  Due to the 
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span of the topic, I was able to locate a wealth of research that provided interesting 
information on current breakthroughs in Africa, in addition to descriptions of assorted 
methods other companies have employed to help combat the costs that result from AIDS 
and the successes and failures each has had.  As a result, although my goal was to research 
specific topics, I often found articles or papers on related issues that still had relevance to 
the model or project.  Therefore, my research also provided me with information and ideas 
regarding sections for further improvement within the model as well as topics for further 
research.  Both issues will be discussed following a synopsis of the primary findings.   
 
V. Research Literature 
 
Although interesting, this topic does prove to be somewhat difficult in terms of available 
research.  The key problem is that most African governments do not maintain accurate 
records.  And, if they do, it is incredibly difficult to access them.  Fortunately, several 
countries, such as South Africa and Botswana, who suffer from two of the highest rates of 
HIV infection, have been keeping appropriate records in recent years.  Thus, due to the 
relative newness of this crisis, most pertinent literature can be found on the Internet.  More 
notably, African companies are a good source for finding case studies that examine the 
effect of different AIDS programs on the workforce and productivity.  In addition to 
companies, many non-profit organizations have been created as a reaction to the 
devastating consequences of the virus.  These organizations have also produced important 
studies of the virus’s effect on African companies and the workforce.  Additionally, for 
very current information regarding antiretroviral drug prices or government policy 
information, I was able to find assorted articles online.  However, there were several case 
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studies upon which I based a great deal of my research conclusions.  Below are brief 
descriptions of each case study. 
  
V.i.  “The Cost of HIV/AIDS to Businesses in South Africa” 
This paper was written by the Center for International Health and Development in 
conjunction with Boston University and the University of California, San Diego. In 
order to determine the costs that businesses suffer due to AIDS, researchers 
compiled data from six different companies and analyzed the results.  This was a 
useful paper  particularly  because all six companies located in South Africa and 
Botswana, which are the areas we intend to market our product.  Due to the 
demographic differences that exist across different African countries, research from 
a company in another country may not accurately reflect the situation in our target 
market.  Thus, information regarding companies in other countries is less beneficial 
to the model.  The companies are in the utility sector, mining and the media.  They 
provided a large range of numbers for each input. 
 
V.ii.  “Care and Treatment to Extend the Working Lives of HIV-Positive    
Employees: Calculating the Benefits to Business  
 
This study was released by the Harvard Institute for International Development.  
Unlike the first study, this study did not provide a set of numbers for several 
different companies.  Rather, it analyzed overall trends, citing different facts from 
various companies.  This study used calculations and formulas to derive a great 
deal of its information.  Finally, using these calculations, the researchers examined 
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the total savings to a company that resulted from treating employees based on three 
scenarios: life expectancy is extended by one year, three years or five years.   
 
V.iii.  “Executive Summary of the HIV/AIDS Study for BP”      
This study was commissioned by BP, a South African petroleum company, to gain 
a better understanding of the effect AIDS was having on its operations.  The paper 
examines each of the costs individually and then looks at the actual values of these 
costs for the next fourteen years under four scenarios.  The four scenarios are that 
BP does not intervene, BP intervenes mildly without using antiretroviral drugs, BP 
intervenes mildly but does distribute antiretroviral drugs and, finally, BP engages in 
strong intervention.  In addition to using company data, the author also used 
demographic data from antenatal clinics in the surrounding area.  
 
V.iv.  “The Economic Impact of  HIV/AIDS in Southern Africa” 
This study was done by The Brookings Institution in Washington, D.C.  This report 
begins by analyzing how some companies initially responded to the crisis when it 
was first recognized as something important.  Ultimately, however, the study 
analyzes what is commonly referred to as the “AIDS tax” on businesses in Africa.  
This is the extra cost that companies suffer as a result of having an AIDS infected 
workforce.  The study examined the costs of three different companies, all located 
in either South Africa or Botswana.   The three companies are in the Heavy 
Industry, Agriculture and Mineral sectors.  The study then provided a detailed 
analysis of Debswana, a large diamond mining company in South Africa.  The 
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analysis not only examined the costs suffered by Debswana, it examined the 
evolution of the company’s policies towards AIDS and its employees. 
 
VI. Chief Conclusions 
 
At the outset of the program, my goal was to determine whether it would be feasible to 
market this program to companies in Africa.  Due to the scope of this topic, however, I am 
unable to successfully answer that question with certainty.  Nonetheless, the research I 
have completed has definitely improved the model.  More importantly, despite changes in 
the model and improvements in assumptions, the model still indicates that use of the 
computer program would bring about positive cash flows.  Although further research is 
necessary, this particular research has helped to reinforce the idea that this project still lies 
within the realm of possibility.  Aside from confirming that this project still has potential 
for success, my research has provided me with some other conclusions regarding the 
model and the marketing of this product.   
  
 IV.i.  Sensitivity of Model 
One key discovery from my research was that certain important assumptions 
change drastically depending on the industry being analyzed.  Due to the model’s 
sensitivity to shifts in these numbers, a change in industry can have an important 
effect on the model’s outcome.  One example is the real discount rate.  Currently, 
the model uses an average of the discount rates used by various South African 
companies in their own studies.  This number, however, is very vulnerable to a 
change in industry or sector.   The study itself provides a good example of the 
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variance hat exists between different industries.  One company in the mineral 
industry used a discount rate of 4.5% while another company in the agriculture 
industry claimed a discount rate equal to 10%.XII  Another variable that is sensitive 
to a change in industry is the infection rate.  In certain industries worker conditions 
have exacerbated the problem.  In the mining industry, for example, workers live in 
community barracks, away from their families, and often take advantage of the 
nearby sex trade.  The prevalence of HIV positive commercial sex workers, 
commonly referred to as CSWs, in large mining communities has helped to create a 
breeding ground for the spread of this disease.XIII  Thus, these conditions have led 
to exceptionally high infection rates, with some mining companies recording rates 
as high as 38%-39%.XIV Although these are only two examples of the changes that 
occur as a result of changing the industry being studied, they help to illustrate the 
importance of changing some assumptions with respect to industry.  This is 
particularly important when analyzing which industries to target.  Using a country-
wide or province average infection rate that lies above the infection rate for an 
industry or company may result in overly optimistic results.  As the project 
progresses, it may be useful to create different versions of the model, each based on 
different industries.  This would be helpful on two levels.  First, the industry 
specific information could be used in deciding which industries or companies to 
target as potential customers.  More accurate assumptions based on industries 
would provide better information regarding which sectors suffer the highest costs 
as a result of AIDS and, thus would be willing to invest in managing those costs.  
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Furthermore, it could then be used to market the program to companies in those 
industries that are designated as being a part of the target market.   
 
  
 IV.ii.  Importance of Skilled Workers 
Overwhelming evidence suggests that there are numerous costs associated with an 
AIDS infected workforce.  Due to the high prices of antiretroviral drugs, however, 
the benefits of treating the workforce may not exceed the costs.  This is particularly 
the case with regards to companies that employ a large number of unskilled 
employees and have a large base of people from which to pull new employees.  
These companies have very low training and recruitment costs and do not have to 
worry about severely depressed levels of productivity after a worker enters the final 
phase of the virus due to the fact that their employees are easily replaceable.  But 
this is not the case for companies that rely on skilled labor.  The costs of training 
are significantly higher for these companies.  They suffer productivity losses from 
the lost employee, the time a healthy employee must spend training new hires, and 
the time it takes the new hire to fully understand their job and achieve full 
productivity.  Hence, antiretroviral treatment can be very beneficial to companies 
that employ high levels of skilled workers, despite astronomical drug prices.  This 
is largely due to the fact that costs associated with an AIDS infected workforce are 
substantially higher for skilled workers.  In a recent study, costs associated with 
skilled workers were roughly 317%-333% those of their unskilled counterparts.XV  
Consequently, it seems logical that companies with many skilled workers should be 
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willing to invest in treatment programs.  Furthermore, some studies show that 
poorly managed treatment programs end up doing more harm than good, as timing 
of medication is critical.  Employees that take antiretroviral drugs at the incorrect 
stage of the virus are actually examples of cost doubling: the cost of the treatment 
along with the cost to the company from past loss in productivity.XVI  The computer 
software would help companies manage their treatment programs at a low cost.  
Therefore, when marketing this product, it would most likely be best to target 
companies with a large percentage of skilled employees. 
 
VII. Areas for Potential Improvement 
 
Although my research has already led to some improvements with regards to the model, 
there are several areas of the model that leave room for further improvement and 
refinement.  It is important to note, though, that when the model was initially put together 
it was intended to be a work in progress.  As a result, it is constantly progressing with 
continued research and data.  Below, I have outlined several larger issues that should be 
considered; however, this is not intended as an exhaustive list.  Due to the ambiguity of 
several of the inputs in the model, it would have been impossible to create a model that 
anticipated all of the facts we have learned through research.  Fortunately, the model was 
constructed with the intention that it would be altered. 
 
 VII.i.  Skilled vs. Unskilled Workers 
As mentioned previously, one of the primary findings of my research was the 
importance of a viable AIDS program for businesses with a large percentage of 
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skilled workers.  The model, however, fails to make a distinction between workers 
with differing skill levels.  The model currently records different figures for salaries 
and for pension cost in termination year, which is derived as a multiple of salary.  
However, it fails to distinguish between many other important costs.  For example, 
as previously discussed, the costs of recruiting and training a new hire to fill the 
position of a skilled employee are very expensive.  Furthermore, the cost of a sick 
day taken by a skilled employee may be greater.  If the skilled employee was a 
supervisor or manager, his/her absence may affect many different workers.  Finally, 
companies may notice different infection rates among skilled workers, as opposed 
to those among non-skilled workers.XVII  By using a model with different figures 
for skilled and unskilled workers, one could accurately demonstrate the sharp 
increase in costs   realized for skilled employees, indicating that the program would 
be perfect for businesses with high levels of skilled employees. 
 
 VII.ii.  Growth Rate of Pharmaceutical Costs 
A hugely debated issue right now regarding the AIDS crisis is the incredibly high 
cost of antiretroviral drugs.  With prices the same in Africa as for most developed 
countries, few families can afford to buy these lifesaving medications.  Countries 
such as Brazil, however, provide an example of ways to avoid this problem.  There, 
generic versions of popular antiretroviral drugs are sold at a small fraction of the 
cost of their name-brand counterparts.  As of September 2002, 63% of 
antiretroviral drugs sold in Brazil were generic copies and overall prices had 
decreased by 82% since 1997.XVIII  Africa expects to see drastic changes in this 
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particular field, as several large pharmaceutical companies have already agreed to 
begin providing drugs at prices equal to the cost of production.  The model 
currently accounts for antiretroviral drugs with two inputs: current price of 
antiretroviral drugs and expected growth in prices of these drugs.  However, this 
methodology does not accurately reflect the current situation.  It is likely that prices 
will experience a sharp decrease, until they reach cost, at which point they should 
grow with inflation.  
 
VIII. Areas for Further Research 
 
Due to the scope of this specific research topic, it requires further work and analysis.  
There are several topics that I have come across during the course of my research that did 
not necessarily fit in with my research at the time but are certainly important factors to 
discuss and will have an impact on the project overall.  Due to the fact that the project 
intends to market a product to companies in Africa, there are many other topics that must 
be considered besides cost and benefit analysis. 
 
 VIII.i.  Target Markets 
As mentioned throughout this paper, a key determinant of this program’s success is 
the amount of laborers employed that are skilled, as opposed to completely 
unskilled.  Prior to marketing this product to companies, it is important to recognize 
which industries could be considered target markets and, specifically, which 
companies may be considered target companies.  After discussing this issue with 
the research team, we felt it would be helpful to create a matrix in which different 
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industries would be judged based on two main criteria.  Those two criteria are the 
use of skilled workers and the availability of replacement workers, or, a labor pool.  
Companies that employ a large percentage of skilled workers and have a very 
limited labor pool from which to hire new employees are target companies and 
would be denoted as such.  Companies that employ a large percentage of skilled 
workers but do not necessarily have a small labor pool would still be denoted as 
potential target companies but are not as desirable as the previous group.  This is 
for several reasons.  As illustrated inn previous sections, the training costs for a 
skilled worker are much higher than those for an unskilled worker.  However, the 
size of the labor pool is important as well.  If companies are able to easily recruit 
and train new employees, they have a slightly decreased incentive to treat sick 
employees that currently work for them, despite burgeoning training costs.  
Companies with a very limited labor pool, however, have an added incentive to 
provide employees with antiretroviral drugs that will extend their life spans.  
Putting together a matrix and designated target industries or  companies would be 
an incredibly  important step prior to developing a marketing strategy.   
Furthermore, it could provide added guidance for developing different versions of 
the model that are designed to apply to specific industrial sectors or companies. 
 
VIII.ii.  Potential Need for Consultant 
Regardless of some companies’ desires to provide employees with an AIDS 
program, they are unsuccessful due to the negative social consequences associated 
with being diagnosed as HIV positive.  Many employees opt not to participate in 
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and AIDS program even though it would make them and their families eligible for 
life-saving drugs at no personal cost.  Furthermore, some employees refuse to be 
tested for HIV in the first place, as they would rather be ignorant of their situation 
than face the consequences of knowing they are, in fact, HIV positive.  Some 
companies have turned to consultants for help.  Image consultants have had some 
success altering the stereotypes that are found in many workplaces.  Using   an 
image consultant would be an added cost in addition to the cost of the program.  
The benefits of that service, however, may very well outweigh the costs.  At 
present, the model assumes that only 25% of employees volunteer themselves for 
free HIV testing and utilize the program.   Even with this incredibly low number, 
the company stands to make a profit by treating its employees.  Therefore, if the 
use of a consultant could increase that number substantially, it would be worth the 
costs of hiring one.  Installing the computer program involves paying for several 
fixed costs, such as the program and the medical staff.  Therefore, it is in a 
company’s best interest to encourage as many employees to be tested and sign up 
for the program as possible, thus maximizing the use of its resources.  Furthermore, 
if a company’s goal is to eliminate the costs associated with AIDS, it will need to 
attract a substantial amount of employees to volunteer for participation in the 






 VIII.iii.  Competition and Tax Code 
There are two more areas that should be researched further as they could potentially 
pose problems that would be too large for the project to overcome.  The first topic 
is competition.  Due to the prevalence of this research topic in the media recently, 
many other researchers have been grappling with potential ways to help alleviate 
some of the escalating costs.  Therefore, it is important to be sure there are no 
similar products on their way to this market.  If there are similar products we may 
choose to either not enter this market or differentiate ourselves either through the 
product or through marketing strategies.  Another issue that should be addressed is 
the tax code.  One particular article mentioned that DeBeers had encountered 
problems when it tried to offer free antiretroviral drugs to its employees.  “One of 
the problems [was] that South African tax laws make the provision of free or 
subsidized medication to employees a taxable benefit, defeating the whole purpose 
of providing free drugs.”XIX   Another problem DeBeers had was that it risked 
violating the Medical Schemes Act, which forbids companies from offering 
services similar to those of medical aid schemes.XX  It seems quite understandable 
that these are issues that would need to be resolved as soon as possible before 




It is rather obvious that the AIDS crisis has had a devastating effect on South Africa’s 
economy and South African businesses.  However, the appropriate way to deal with the 
costs of this crisis is far less obvious.  As this epidemic continues to ravage the workforce, 
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companies have begun to recognize the benefits of providing healthcare plans to its 
employees.  Companies should be willing to purchase fairly priced computer software that 
would help them to properly manage their AIDS programs, which would help to mitigate 
some of the staggering costs that have resulted from the spread of the virus.  In order to 
determine the feasibility of this business plan, a financial model should relate whether the 
benefits of treating workers justify the costs of the program.  Additionally, as the research 
progresses, the model should be constantly improved in order to reflect current 
information.  Due to the increased costs of skilled workers, companies employing large 
amounts of skilled workers should be targeted as potential customers.  Furthermore, 
companies with a limited labor pool are even more desirable candidates.  These are some 
general guidelines regarding appropriate companies to target as potential customers.  
However, further research is necessary regarding these criteria and further adjustments to 
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Growth rate of pharmaceutical costs
Pension cost in termination year
Annual Exchange Rate Fluctuation
Unskilled worker salary (annual)
Working life extension from first ARV
Base working lifespan of infected employ
real discount rate (from IMF)
Working life extension from second ARV
Wage inflation
Required ROI to company
Monthly cost of second round ARV
Monthly cost of first round ARV
Cost of sick day
Recruitment/training cost in termination
Monthly cost per employee incurred inter
Additional sick days per year in last tw
Time lag to productivity improvement (sk
Productivity Improvement (unskilled)
Time lag to productivity improvement
Number of employees
Skilled worker salary (annual)
HIV infected employees who will enroll
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